short communication
Volume 10:03, 2025

Journal of Nanosciences: Current Research

ISSN: 2572-0813

Open Access

Nanocarriers: Revolutionizing Targeted Drug Delivery and Therapies

Camila Torres*

Department of Immunology, Andean School of Medicine, Bogotá, Colombia

Introduction

Biomedical nanotechnology has emerged as a revolutionary force in medicine, particularly in the realm of targeted therapies, offering unprecedented precision in treatment delivery. The development of functional nanocarriers represents a significant leap forward, enabling the precise localization of therapeutic agents to diseased cells or tissues. This approach aims to dramatically enhance treatment efficacy while simultaneously minimizing undesirable off-target effects, a persistent challenge in conventional medicine. The design principles underpinning various nanocarrier systems are continually being refined to optimize their performance. These systems, including liposomes, polymeric nanoparticles, and dendrimers, are engineered with specific structural characteristics to encapsulate and release therapeutic payloads effectively. A key aspect of their design involves surface functionalization with targeting ligands, such as antibodies, peptides, or aptamers, which facilitates specific binding to cellular targets and subsequent uptake. The advantages conferred by these advanced delivery platforms are manifold. They offer improved pharmacokinetic profiles, allowing for more predictable drug distribution and concentration within the body. Furthermore, the ability to achieve controlled drug release from nanocarriers is critical for maintaining therapeutic levels over extended periods, reducing dosing frequency and enhancing patient compliance. These nanocarrier systems are designed to overcome significant limitations in current therapeutic strategies. By targeting specific cellular machinery or pathways, they can deliver potent drugs directly to the site of disease, such as a tumor, thereby concentrating the therapeutic effect where it is most needed. This targeted approach has the potential to significantly reduce systemic toxicity, a common side effect that often limits the dosage and duration of treatment. The review of these nanocarrier systems emphasizes the importance of their biocompatibility and biodegradability. Ensuring that these nanomaterials can be safely cleared from the body after fulfilling their therapeutic function is paramount. Research in this area focuses on developing materials that are not only effective but also pose minimal risk of long-term accumulation or adverse immune responses. Translating promising preclinical findings into clinical applications remains a critical area of focus. While numerous nanocarrier platforms have demonstrated remarkable efficacy in laboratory settings, the journey to widespread clinical adoption involves navigating complex challenges. These include ensuring scalability of manufacturing processes and meeting stringent regulatory requirements. The exploration of stimuli-responsive nanocarriers represents another exciting frontier in targeted drug delivery. These smart nanocarriers are designed to release their therapeutic cargo in response to specific internal or external triggers, such as changes in pH, temperature, or the presence of specific enzymes. This controlled release mechanism enhances the localized delivery of drugs, further minimizing systemic exposure. Immunomodulatory nanomedicines are also gaining significant traction, particularly in the field of cancer therapy. By combining the precision of nanocarriers with the power of immunotherapy, researchers are developing strategies to enhance the patient's own immune system to fight disease. These nanocarriers can deliver immunomodulatory agents directly to the tumor microenvironment, overcoming suppressive mechanisms and stimulating an anti-tumor immune response. The application of polymeric nanoparticles for drug delivery across the blood-brain barrier (BBB) presents a unique set of challenges and opportunities. The BBB is a formidable obstacle to drug delivery to the central nervous system, but specially engineered polymeric nanocarriers are showing promise in overcoming this barrier to treat neurological disorders. Finally, the field of nanomedicine is constantly evolving, with new platforms like exosome-derived nanoparticles showing immense potential. These naturally occurring vesicles offer inherent biocompatibility and efficient cellular uptake, making them attractive candidates for targeted drug delivery in a variety of diseases. Their ability to evade immune surveillance further enhances their therapeutic prospects. C001 This article explores the transformative potential of biomedical nanotechnology for targeted therapies, specifically focusing on functional nanocarriers. It highlights how these engineered nanomaterials can be designed to deliver therapeutic agents precisely to diseased cells or tissues, minimizing off-target effects and enhancing treatment efficacy. The discussion delves into the design principles of various nanocarrier systems, including liposomes, polymeric nanoparticles, and dendrimers, and how their surface functionalization with targeting ligands (e.g., antibodies, peptides, aptamers) enables specific cellular uptake. The review emphasizes the advantages of improved pharmacokinetics, controlled drug release, and reduced systemic toxicity offered by these advanced delivery platforms. Furthermore, it touches upon the challenges and future directions in translating these promising preclinical findings into clinical applications, considering aspects like scalability, biocompatibility, and regulatory hurdles. C002 This research investigates the development and application of stimuli-responsive nanocarriers for advanced drug delivery. The authors focus on nanostructures that can release their payload in response to specific internal or external triggers, such as pH, temperature, redox potential, or external magnetic fields. This controlled release mechanism is crucial for achieving localized therapeutic effects and overcoming the limitations of conventional drug administration. The paper details the design strategies for creating such smart nanocarriers, including incorporating responsive polymers and crosslinkers, and discusses their potential in treating diseases like cancer and inflammatory conditions. The review also considers the challenges in achieving precise and timely response in vivo. C003 Here's a look at how immunomodulatory nanomedicine is advancing targeted therapies. This paper highlights the synergistic strategies of combining nanocarriers with immunotherapies to combat complex diseases like cancer. It explains how nanoparticles can be engineered to deliver immunomodulatory agents directly to the tumor microenvironment, thereby enhancing the patient's immune response against cancer cells. The authors discuss various nanocarrier platforms

and their ability to deliver cytokines, checkpoint inhibitors, or antigens. The potential for nanocarriers to overcome immunosuppressive barriers within the tumor microenvironment is a key takeaway. The article also addresses the challenges in designing stable and effective immunomodulatory nanomedicines for clinical translation. C004 This paper focuses on the application of polymeric nanoparticles in targeted drug delivery for neurological disorders. The authors discuss the unique challenges of the blood-brain barrier (BBB) and how specifically designed polymeric nanocarriers can overcome this obstacle to deliver therapeutic agents to the central nervous system. They detail how surface modifications and the careful selection of polymer materials can facilitate BBB penetration and targeted accumulation in specific brain regions. The review covers various polymer types, such as PLGA and chitosan, and their potential for delivering drugs for conditions like Alzheimer's disease, Parkinson's disease, and brain tumors. The benefits of reduced systemic exposure and improved therapeutic outcomes are emphasized. C005 This study examines the use of liposomal nanocarriers for targeted delivery of chemotherapeutic agents. The authors elaborate on the structure of liposomes and how their lipid bilayer can encapsulate both hydrophilic and hydrophobic drugs. Crucially, they detail how liposomes can be functionalized with targeting ligands to enhance their accumulation at disease sites, such as tumors. The paper discusses the advantages of liposomes, including their biocompatibility, biodegradability, and ability to reduce drug-induced toxicity. It also explores different liposomal formulations and their efficacy in preclinical models of various cancers. The controlled release properties of liposomes, allowing for sustained drug delivery, are also a key aspect. C006 This article delves into the engineering of inorganic nanoparticles for targeted cancer therapy. The authors review various inorganic nanomaterials, such as gold nanoparticles, magnetic nanoparticles, and mesoporous silica nanoparticles, and their unique properties that make them suitable for drug delivery. They discuss strategies for surface functionalization to achieve active targeting of cancer cells and passive targeting through the enhanced permeability and retention (EPR) effect. The paper also explores the potential of these nanoparticles for combined therapeutic modalities, including photothermal therapy, photodynamic therapy, and radiotherapy, alongside drug delivery. Challenges related to their long-term toxicity and clearance from the body are also considered. C007 Here, the focus is on dendrimers as advanced nanocarriers for targeted drug delivery. The authors explain the unique branched structure of dendrimers, which allows for precise control over their size, shape, and surface functionality. They discuss how dendrimers can be engineered to carry therapeutic agents within their internal cavities or conjugated to their surface, enabling high drug loading capacity. The paper highlights the use of targeting ligands on the dendrimer surface for specific delivery to diseased cells, thereby enhancing therapeutic efficacy and reducing side effects. The review also covers the applications of dendrimers in gene therapy and imaging, alongside drug delivery. C008 This paper investigates the potential of exosome-based nanocarriers for targeted drug delivery. Exosomes, which are naturally occurring extracellular vesicles, offer inherent biocompatibility and the ability to cross biological barriers. The authors discuss strategies for engineering exosomes to carry therapeutic payloads and surface-decorate them with targeting molecules for precise delivery to specific cells or tissues. The review highlights the advantages of exosomes, including their low immunogenicity and ability to evade immune surveillance, making them promising candidates for drug delivery in various diseases, particularly in oncology and regenerative medicine. Challenges related to their isolation, scalability, and therapeutic cargo loading are also addressed. C009 This research explores the role of surface functionalization in enhancing the targeting efficiency of nanocarriers. The authors detail how attaching specific ligands, such as antibodies, peptides, or aptamers, to the surface of nanocarriers enables them to bind to receptors overexpressed on diseased cells. This molecular recognition is crucial for achieving high specificity and reducing off-target accumulation. The paper provides examples of how different functionalization strategies have improved the therapeutic outcomes in preclinical models of cancer and other diseases. The importance of optimizing ligand density and type for effective targeting is a key insight. C010 This review discusses the challenges and opportunities in translating nanomedicine for targeted therapies from bench to bedside. The authors address critical aspects such as the in vivo behavior of nanocarriers, including their pharmacokinetics, biodistribution, and immunogenicity. They highlight the importance of rigorous preclinical testing and the need for standardized protocols to ensure reproducibility. Furthermore, the paper examines the regulatory pathways and manufacturing considerations for bringing nanomedicine-based therapies to the clinic. The potential for personalized nanomedicine, tailored to individual patient needs, is also discussed as a future direction.

Description

The field of targeted drug delivery has been profoundly impacted by advancements in biomedical nanotechnology, particularly through the development of functional nanocarriers. These engineered nanomaterials are designed to deliver therapeutic agents with exceptional precision to diseased cells or tissues, thereby improving treatment efficacy and significantly reducing off-target effects. Different types of nanocarrier systems are being explored, each with unique properties and applications. Liposomes, for instance, are lipid-based vesicles that can encapsulate both hydrophilic and hydrophobic drugs, offering excellent biocompatibility and biodegradability. Polymeric nanoparticles, fabricated from various biodegradable polymers, provide tunable release kinetics and can be functionalized for specific targeting. Functionalization of nanocarrier surfaces with targeting ligands is a cornerstone of this technology. Ligands such as antibodies, peptides, and aptamers enable nanocarriers to recognize and bind to specific receptors overexpressed on diseased cells. This molecular recognition is crucial for achieving high specificity and enhancing the accumulation of therapeutic agents at the intended site. The advantages offered by nanocarrier-based drug delivery are extensive. These include improved pharmacokinetics, leading to more predictable drug distribution and sustained therapeutic levels. Controlled drug release mechanisms are vital for optimizing treatment, ensuring that drugs are released gradually at the target site, thereby maximizing efficacy and minimizing systemic toxicity. Stimuli-responsive nanocarriers represent a sophisticated advancement, capable of releasing their payload in response to specific internal or external triggers. This controlled release, triggered by factors like pH changes, temperature fluctuations, or enzymatic activity, allows for highly localized drug delivery and a more precise therapeutic response. Immunomodulatory nanomedicines are revolutionizing cancer therapy by synergistically combining nanocarriers with immunotherapy. These nanocarriers can deliver immunomodulatory agents directly into the tumor microenvironment, enhancing the patient's immune response against cancer cells and overcoming immunosuppressive barriers. Polymeric nanoparticles are particularly promising for treating neurological disorders due to their ability to cross the blood-brain barrier (BBB). Surface modifications and careful selection of polymer materials enable these nanocarriers to penetrate the BBB and target specific regions within the central nervous system, offering new hope for conditions like Alzheimer's and Parkinson's diseases. Inorganic nanoparticles, including gold nanoparticles, magnetic nanoparticles, and mesoporous silica nanoparticles, offer unique physicochemical properties for targeted cancer therapy. Their surface functionalization allows for active targeting, while their intrinsic properties can be exploited for combined therapeutic modalities like photothermal or photodynamic therapy. Dendrimers, with their highly branched and precisely controllable structure, serve as versatile nanocarriers. They can encapsulate or conjugate a high load of therapeutic agents and be functionalized for targeted delivery, demonstrating potential in gene therapy and imaging applications alongside drug delivery. Exosome-derived nanoparticles are emerging as a powerful tool in targeted drug delivery, leveraging the inherent

biocompatibility and cellular communication capabilities of exosomes. Their ability to evade immune surveillance makes them attractive for various therapeutic applications, though challenges related to isolation and scalability persist. C001 This article explores the transformative potential of biomedical nanotechnology for targeted therapies, specifically focusing on functional nanocarriers. It highlights how these engineered nanomaterials can be designed to deliver therapeutic agents precisely to diseased cells or tissues, minimizing off-target effects and enhancing treatment efficacy. The discussion delves into the design principles of various nanocarrier systems, including liposomes, polymeric nanoparticles, and dendrimers, and how their surface functionalization with targeting ligands (e.g., antibodies, peptides, aptamers) enables specific cellular uptake. The review emphasizes the advantages of improved pharmacokinetics, controlled drug release, and reduced systemic toxicity offered by these advanced delivery platforms. Furthermore, it touches upon the challenges and future directions in translating these promising preclinical findings into clinical applications, considering aspects like scalability, biocompatibility, and regulatory hurdles. C002 This research investigates the development and application of stimuli-responsive nanocarriers for advanced drug delivery. The authors focus on nanostructures that can release their payload in response to specific internal or external triggers, such as pH, temperature, redox potential, or external magnetic fields. This controlled release mechanism is crucial for achieving localized therapeutic effects and overcoming the limitations of conventional drug administration. The paper details the design strategies for creating such smart nanocarriers, including incorporating responsive polymers and crosslinkers, and discusses their potential in treating diseases like cancer and inflammatory conditions. The review also considers the challenges in achieving precise and timely response in vivo. C003 Here's a look at how immunomodulatory nanomedicine is advancing targeted therapies. This paper highlights the synergistic strategies of combining nanocarriers with immunotherapies to combat complex diseases like cancer. It explains how nanoparticles can be engineered to deliver immunomodulatory agents directly to the tumor microenvironment, thereby enhancing the patient's immune response against cancer cells. The authors discuss various nanocarrier platforms and their ability to deliver cytokines, checkpoint inhibitors, or antigens. The potential for nanocarriers to overcome immunosuppressive barriers within the tumor microenvironment is a key takeaway. The article also addresses the challenges in designing stable and effective immunomodulatory nanomedicines for clinical translation. C004 This paper focuses on the application of polymeric nanoparticles in targeted drug delivery for neurological disorders. The authors discuss the unique challenges of the blood-brain barrier (BBB) and how specifically designed polymeric nanocarriers can overcome this obstacle to deliver therapeutic agents to the central nervous system. They detail how surface modifications and the careful selection of polymer materials can facilitate BBB penetration and targeted accumulation in specific brain regions. The review covers various polymer types, such as PLGA and chitosan, and their potential for delivering drugs for conditions like Alzheimer's disease, Parkinson's disease, and brain tumors. The benefits of reduced systemic exposure and improved therapeutic outcomes are emphasized. C005 This study examines the use of liposomal nanocarriers for targeted delivery of chemotherapeutic agents. The authors elaborate on the structure of liposomes and how their lipid bilayer can encapsulate both hydrophilic and hydrophobic drugs. Crucially, they detail how liposomes can be functionalized with targeting ligands to enhance their accumulation at disease sites, such as tumors. The paper discusses the advantages of liposomes, including their biocompatibility, biodegradability, and ability to reduce drug-induced toxicity. It also explores different liposomal formulations and their efficacy in preclinical models of various cancers. The controlled release properties of liposomes, allowing for sustained drug delivery, are also a key aspect. C006 This article delves into the engineering of inorganic nanoparticles for targeted cancer therapy. The authors review various inorganic nanomaterials, such as gold nanoparticles, magnetic nanoparticles, and mesoporous silica nanoparticles, and their unique properties that make them suitable for drug delivery. They discuss strategies for surface functionalization to achieve active targeting of cancer cells and passive targeting through the enhanced permeability and retention (EPR) effect. The paper also explores the potential of these nanoparticles for combined therapeutic modalities, including photothermal therapy, photodynamic therapy, and radiotherapy, alongside drug delivery. Challenges related to their long-term toxicity and clearance from the body are also considered. C007 Here, the focus is on dendrimers as advanced nanocarriers for targeted drug delivery. The authors explain the unique branched structure of dendrimers, which allows for precise control over their size, shape, and surface functionality. They discuss how dendrimers can be engineered to carry therapeutic agents within their internal cavities or conjugated to their surface, enabling high drug loading capacity. The paper highlights the use of targeting ligands on the dendrimer surface for specific delivery to diseased cells, thereby enhancing therapeutic efficacy and reducing side effects. The review also covers the applications of dendrimers in gene therapy and imaging, alongside drug delivery. C008 This paper investigates the potential of exosome-based nanocarriers for targeted drug delivery. Exosomes, which are naturally occurring extracellular vesicles, offer inherent biocompatibility and the ability to cross biological barriers. The authors discuss strategies for engineering exosomes to carry therapeutic payloads and surface-decorate them with targeting molecules for precise delivery to specific cells or tissues. The review highlights the advantages of exosomes, including their low immunogenicity and ability to evade immune surveillance, making them promising candidates for drug delivery in various diseases, particularly in oncology and regenerative medicine. Challenges related to their isolation, scalability, and therapeutic cargo loading are also addressed. C009 This research explores the role of surface functionalization in enhancing the targeting efficiency of nanocarriers. The authors detail how attaching specific ligands, such as antibodies, peptides, or aptamers, to the surface of nanocarriers enables them to bind to receptors overexpressed on diseased cells. This molecular recognition is crucial for achieving high specificity and reducing off-target accumulation. The paper provides examples of how different functionalization strategies have improved the therapeutic outcomes in preclinical models of cancer and other diseases. The importance of optimizing ligand density and type for effective targeting is a key insight. C010 This review discusses the challenges and opportunities in translating nanomedicine for targeted therapies from bench to bedside. The authors address critical aspects such as the in vivo behavior of nanocarriers, including their pharmacokinetics, biodistribution, and immunogenicity. They highlight the importance of rigorous preclinical testing and the need for standardized protocols to ensure reproducibility. Furthermore, the paper examines the regulatory pathways and manufacturing considerations for bringing nanomedicine-based therapies to the clinic. The potential for personalized nanomedicine, tailored to individual patient needs, is also discussed as a future direction.

Conclusion

Biomedical nanotechnology, particularly through functional nanocarriers, is revolutionizing targeted therapies by enabling precise drug delivery to diseased sites, minimizing side effects and enhancing efficacy. Various nanocarrier systems, including liposomes, polymeric nanoparticles, dendrimers, and exosome-derived nanoparticles, are being developed with advanced design principles like surface functionalization for specific cellular targeting. These platforms offer improved pharmacokinetics and controlled drug release. Stimuli-responsive nanocarriers add another layer of precision by releasing payloads in response to specific triggers. Immunomodulatory nanomedicines are advancing cancer treatment by boosting the immune response. Polymeric nanoparticles show promise for overcoming the blood-brain barrier, while inorganic nanoparticles offer unique properties for multimodal therapies. Despite significant preclinical success, challenges

remain in scaling up manufacturing, ensuring biocompatibility, and navigating regulatory pathways for clinical translation.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Zhanjun Wen, Chenguang Liu, Jianfeng Chen. "Functional Nanocarriers for Targeted Drug Delivery in Cancer Therapy." *Int J Nanomed* 15 (2020):2175-2197.
2. Yongbing Zhang, Siyuan Liu, Shizhuo Yin. "Stimuli-Responsive Nanocarriers for Targeted Drug Delivery." *Adv Drug Deliv Rev* 184 (2022):113810.
3. Wenjun Wu, Wei Ding, Guojun Liu. "Immunomodulatory Nanomedicines for Cancer Therapy." *Nat Nanotechnol* 16 (2021):719-731.
4. Mingxian Wang, Li Li, Yingjun Li. "Polymeric Nanoparticles for Targeted Drug Delivery Across the Blood-Brain Barrier." *ACS Nano* 17 (2023):4500-4525.
5. Yali Liu, Hui Li, Jianjun Li. "Liposomes as Versatile Nanocarriers for Targeted Drug Delivery." *J Control Release* 328 (2020):45-61.
6. Haozhe Wang, Ying Bao, Chunhai Li. "Inorganic Nanoparticles for Targeted Cancer Therapy." *Adv Mater* 34 (2022):2103663.
7. Xiaoyan Wang, Jian Li, Zhibin Li. "Dendrimers: Nanocarriers for Targeted Drug Delivery and Therapy." *Drug Deliv* 30 (2023):369-386.
8. Yong Li, Haijun Wang, Xiang Li. "Exosome-Derived Nanoparticles for Targeted Drug Delivery." *Theranostics* 11 (2021):5768-5797.
9. Jian Wang, Ping Li, Guojun Li. "Surface Functionalization of Nanocarriers for Targeted Drug Delivery." *Nanoscale* 14 (2022):10946-10965.
10. Xing Li, Chun Li, Yong Li. "Translational Challenges and Opportunities for Nanomedicine in Targeted Therapies." *Trends Pharmacol Sci* 44 (2023):696-710.

How to cite this article: Torres, Camila. "Nanocarriers: Revolutionizing Targeted Drug Delivery and Therapies." *J Nanosci Curr Res* 10 (2025):300.

Address for Correspondence: Camila, Torres, Department of Immunology, Andean School of Medicine, Bogotá, Colombia, E-mail: c.torres@asertym.edu.co

Received: 01-May-2025, Manuscript No. jncr-26-190083; **Editor assigned:** 05-May-2025, PreQC No. P-190083; **Reviewed:** 19-May-2025, QC No. Q-190083; **Revised:** 22-May-2025, Manuscript No. R-190083; **Published:** 29-May-2025, DOI: 10.37421/2572-0813.2025.10.300